Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19?
Mol Med
; 26(1): 80, 2020 08 17.
Article
in English
| MEDLINE | ID: covidwho-717479
ABSTRACT
Infection of lung cells by the corona virus results in a loss of the balance between, on the one hand, angiotensin II-mediated stimulation of the angiotensin II type 1 receptor and, on the other hand, stimulation of the angiotensin II type 2 receptor and/or the Mas receptor. The unbalanced enhanced stimulation of the angiotensin II type 1 receptor causes inflammation, edema and contributes to the pathogenesis of severe acute respiratory distress syndrome. Here we hypothesize that stable, receptor-specific agonists of the angiotensin II type 2 receptor and of the Mas receptor are molecular medicines to treat COVID-19 patients. These agonists have therapeutic potential in the acute disease but in addition may reduce COVID-19-associated long-term pulmonary dysfunction and overall end-organ damage of this disease.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Renin-Angiotensin System
/
Peptidyl-Dipeptidase A
/
Receptor, Angiotensin, Type 2
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Animals
/
Humans
Language:
English
Journal:
Mol Med
Journal subject:
Molecular Biology
Year:
2020
Document Type:
Article
Affiliation country:
S10020-020-00211-0
Similar
MEDLINE
...
LILACS
LIS